Skip Navigation
Skip to contents

JYMS : Journal of Yeungnam Medical Science

Indexed in: ESCI, Scopus, PubMed,
PubMed Central, CAS, DOAJ, KCI
OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
2 "Immune checkpoint inhibitors"
Filter
Filter
Article category
Keywords
Publication year
Authors
Case reports
Adrenal insufficiency development during chemotherapy plus anti-programmed death receptor-1 monoclonal antibody (tislelizumab) therapy in patients with advanced gastric cancer: two case reports
Jin Ho Baek
J Yeungnam Med Sci. 2022;39(1):62-66.   Published online April 19, 2021
DOI: https://doi.org/10.12701/yujm.2021.00934
  • 4,650 View
  • 99 Download
  • 3 Citations
AbstractAbstract PDF
Immune checkpoint inhibitor (ICI)-associated adrenal insufficiency is rare but may become a serious adverse event in patients treated with ICIs. The present case report documents two cases of adrenal insufficiency developed during chemotherapy plus tislelizumab (百泽安, Baize’an; BeiGene Ltd.) therapy in patients with advanced gastric cancer. Adrenal insufficiency developed after 6 and 13 cycles of treatment and was well controlled with hydrocortisone. The patients also developed hypothyroidism, which was managed with levothyroxine. Two patients showed a partial response, and one patient out of two achieved a near-complete response, sustaining over 11 months. Increased awareness of ICI-related adrenal insufficiency is crucial for early detection and prompt management of patients treated with ICIs.

Citations

Citations to this article as recorded by  
  • Severe thyrotoxicosis induced by tislelizumab: a case report and literature review
    Liman Huo, Chao Wang, Haixia Ding, Xuelian Shi, Bin Shan, Ruoying Zhou, Ping Liang, Juan Hou
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Immune-related adverse events with severe pain and ureteral expansion as the main manifestations: a case report of tislelizumab-induced ureteritis/cystitis and review of the literature
    Qihao Zhou, Zhiquan Qin, Peiyuan Yan, Qunjiang Wang, Jing Qu, Yun Chen
    Frontiers in Immunology.2023;[Epub]     CrossRef
  • Isolated Renal Calyceal Urothelial Carcinoma Effectively Treated With PD-1 Inhibitor Alone: A Case Report And Literature Review
    Shihao Li, Yi Zhu, Zhijian Xu, Jianjun Liu, Hongwei Liu
    Frontiers in Oncology.2022;[Epub]     CrossRef
Pembrolizumab-related autoimmune hemolytic anemia in a patient with metastatic lung adenocarcinoma: a case report
Dong Won Baek, Yee Soo Chae
Yeungnam Univ J Med. 2021;38(4):366-370.   Published online March 23, 2021
DOI: https://doi.org/10.12701/yujm.2021.00899
  • 4,580 View
  • 117 Download
  • 5 Citations
AbstractAbstract PDF
Immune checkpoint inhibitors (ICIs) have become the main drugs for programmed cell death receptor-1 or ligand-1 expressing non-small cell lung cancer (NSCLC) combined with conventional chemotherapy. ICIs are generally more tolerable than cytotoxic chemotherapies in terms of toxicity, and ICI-related adverse events are mild and manageable. However, these drugs may lead to unexpected severe adverse events such as immune-related hematologic toxicities, which could be life-threatening. Here, a rare case of a pembrolizumab-related adverse event in a patient with NSCLC who showed early-onset hemolytic anemia and recovered by high-dose steroid and a series of plasma exchanges is reported.

Citations

Citations to this article as recorded by  
  • Case Report: Life-threatening pancytopenia with tislelizumab followed by cerebral infarction in a patient with lung adenocarcinoma
    Hang-Yu Gu, Jing-Wen Zhao, Yin-Shuang Wang, Zhuo-Nan Meng, Xiu-Ming Zhu, Fu-Wei Wang, Ai-Hong Zheng, Guo-Qing Wu
    Frontiers in Immunology.2023;[Epub]     CrossRef
  • Immunotherapy-associated Autoimmune Hemolytic Anemia
    Steven R. Hwang, Antoine N. Saliba, Alexandra P. Wolanskyj-Spinner
    Hematology/Oncology Clinics of North America.2022; 36(2): 365.     CrossRef
  • Therapeutic plasma exchange in the management of immune checkpoint inhibitor‐associated immune‐related adverse effects: A review
    Oluwatoyosi A. Onwuemene, Chizoba I. Nnoruka, Christopher J. Patriquin, Laura S. Connelly‐Smith
    Transfusion.2022; 62(11): 2370.     CrossRef
  • Diagnosis and management of cold agglutinin disease associated with low-grade B-cell lymphoma in a patient receiving pembrolizumab for lung cancer
    Nabin Raj Karki, Peyton McElhone, Natasha Savage, Nagla Abdel Karim
    BMJ Case Reports.2021; 14(8): e243751.     CrossRef
  • Red Blood Cell Autoantibodies in Patients Treated with Immune Checkpoint Inhibitors
    Eungjun Yoon, Tae Yeul Kim, Sun Kyoung Mun, Duck Cho
    The Korean Journal of Blood Transfusion.2021; 32(3): 201.     CrossRef

JYMS : Journal of Yeungnam Medical Science